M2 Europharma articles from July 2002

M2 Europharma archives from July 2002

Novo Nordisk launches diabetes pill.(Brief Article)(Product Announcement)
July 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish pharmaceutical group Novo Nordisk has reportedly introduced a new pill for treating diabetes. The development of the new medicine started in the 1980s and has cost over...

Oxford BioMedica and ARIUS Research form tumour immunotherapy collaboration.(Brief Article)
July 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based biotechnology company Oxford BioMedica Plc has formed a research and development collaboration with ARIUS Research Inc of Canada. Under the partnership the companies will...

Boots doubles capacity for Botox treatments.(Brief Article)
July 31, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK drug and personal care products retailer Boots Plc is to double the capacity of its trial stores offering Botox injections. Boots has seen great demand for the wrinkle-removing...

Bayer delays launch of Vardenafil impotence drug.(Brief Article)
July 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceuticals and chemicals group Bayer AG has reportedly pushed back the launch of Vardenafil, its rival to Pfizer's impotence drug Viagra. Vardenafil will not be launched...

Lundbeck releases Ebixa trial results.(Brief Article)
July 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish pharmaceutical company H. Lundbeck A/S has released positive results from a six-month placebo-controlled trial of its Alzheimer's disease drug Ebixa. The study indicated that...

Pharmagene and GlaxoSmithKline enter new agreement.(Brief Article)
July 30, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based drug discovery company Pharmagene Plc has signed a compound validation agreement with GlaxoSmithKline. Under the terms of the agreement, GlaxoSmithKline will gain access to...

Siemens Medical Solutions wins US pre-market approval for tennis elbow therapy system.(SONOCUR Basic)(Brief Article)(Product Announcement)
July 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Healthcare equipment supplier Siemens Medical Solutions, a unit of Germany's Siemens AG, has won pre-market approval in the US for its SONOCUR Basic pain therapy system. SONOCUR Basic...

British Biotech and BresaGen end E21R collaboration. (GM-CSF antagonist).(Brief Article)
July 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD British Biotech Plc and Australia's BresaGen Ltd have terminated their collaborative agreement to develop the GM-CSF antagonist E21R. The decision to end the collaboration followed a...

Genmab to delist its share from Frankfurt.(Brief Article)
July 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish biotechnology company Genmab A/S is to delist its share from the Neuer Markt list of the Frankfurt stock exchange in Germany. Genmab mentioned excessive costs from duplicate...

Spain's Farmaindustria announces EUR1.35bn research investment.(Brief Article)
July 29, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Farmaindustria, the national association of the pharmaceutical industry in Spain, is to invest EUR1.35bn for research and development by the end of 2007. Of this, EUR450m will be...

Genetix forms human protein interaction mapping collaboration.(Brief Article)
July 26, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based Genetix Group Plc has formed a GBP2.5m collaboration with the Medical Research Council's Human Genome Mapping Project Resource Centre to build a verified human protein-protein...

NICE recommends Schering-Plough cancer drug.(National Institute for Clinical Excellence )(Brief Article)(Statistical Data Included)
July 26, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK's National Institute for Clinical Excellence (NICE) has approved a cancer drug from US-based pharmaceutical company Schering-Plough Corp for the treatment of women with advanced...

Bayer wins immunoassay products supply contract in the US.(Brief Article)
July 26, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Bayer Corp, part of the German chemicals and pharmaceuticals company Bayer Group, has won a contract to supply immunoassay products to members of Novation, a US-based contract purchaser...

Berna Biotech acquires 83.4% of Rhein Biotech shares, extends offer period.(Brief Article)
July 26, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Switzerland-based vaccine producer Berna Biotech AG has successfully completed its tender offer for the acquisition of shares in Rhein Biotech NV, a global biotechnology group. A...

Pain relief patch launched in Europe by Gruenenthal GmbH.(Brief Article)
July 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Gruenenthal GmbH has released a new pain control patch treatment. Transtec is a thin, rectangular polymer patch which contains the pain-killing drug...

US panel agrees that AstraZeneca can promote Atacand as superior to rival.(Brief Article)
July 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A US federal panel has said that Anglo-Swedish drug group AstraZeneca Plc should be able to promote its high blood pressure medicine Atacand as superior to Merck & Co's Cozaar drug. ...

Spain's Zeltia restructures Pharma Gen unit.(Zeltia S.A. sells off two vaccines companies, merges Pharma Gen S.A., Genomica)(Brief Article)
July 25, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Spanish chemicals company Zeltia SA is restructuring its Pharma Gen SA unit to focus on molecular and gene investigation. As part of the reorganisation Zeltia has sold off two...

deCODE publishes findings of schizophrenia research.(Brief Article)
July 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Iceland's deCODE genetics has released a paper about the company's work on the genetics of schizophrenia. Due to be published in the October 2002 edition of the American Journal of...

Bianucci to sell Biofield's breast cancer detection system in Italy.(Bianucci di Bianucci and C snc, Biofield Corp.)(Brief Article)
July 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Bianucci di Bianucci & C snc has been appointed as the exclusive distributor in Italy of Biofield Corp's Biofield Diagnostic System (BDS). The BDS is used by healthcare providers to...

Sanofi-Synthelabo to sell Elitek in the US from August.(Brief Article)
July 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD French pharmaceutical company Sanofi-Synthelabo plans to launch its Elitek cancer drug in the US market in August. The US Food and Drug Administration has approved Sanofi-Synthelabo's...

Novo Nordisk suspends clinical development of ragaglitazar.(Brief Article)
July 24, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish healthcare company Novo Nordisk A/S has suspended the clinical development of its dual-acting insulin sensitiser ragaglitazar (NN622). The decision was taken in response to...

Pharmagene signs agreements with Japanese pharmaceutical firms.(Pharmagene PLC, Ono Pharmaceutical Company Ltd., Sankyo Company Ltd., Taisho Pharmaceutical Company Ltd.)(Brief Article)
July 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based drug discovery company Pharmagene Plc has signed agreements with three Japanese pharmaceutical companies. Under an agreement with Ono Pharmaceutical Co Ltd, the Japanese...

Schering AG receives Austrian approval for new acne gel.(Brief Article)
July 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Schering AG has been granted approval to market its new SKINOREN GEL acne treatment in Austria. Schering will use the approval to form the basis of a...

Spanish pharmacies begin selling drug detection kit.(Brief Article)
July 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A drug detection kit designed for parents to test teenagers for four types of banned narcotics has gone on sale in Spain. The kit, marketed under the name Arifarmtest, is claimed to...

Pharmaco makes offer for all shares in Delta.(Brief Article)(Statistical Data Included)
July 23, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Icelandic pharmaceutical company Pharmaco hf has made an offer for all remaining shares in Delta hf, an Icelandic drug manufacturer. Pharmaco acquired 51% of Delta on Friday (19 July)...

GlaxoSmithKline loses UK legal challenge to Paxil patent.(Brief Article)
July 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A UK court has partly overturned the patent on UK-based GlaxoSmithKline Plc's antidepressant Paxil. The High Court ruled that parts of GlaxoSmithKline's patent covering paroxetine...

Genmab A/S and JARI Pharmaceuticals BV form antibody collaboration.(Brief Article)
July 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish biotechnology company Genmab A/S has formed an alliance with JARI Pharmaceuticals BV of the Netherlands to develop new antibody therapeutic products. Under the partnership JARI...

Inpharmatica signs up first Japanese client.(Brief Article)
July 22, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based drug discovery company Inpharmatica Ltd has signed a deal with Daiichi Pharmaceutical Co Ltd, a Japanese pharmaceutical company. Under the agreement Daiichi has taken a...

Oxford Biomedica's cancer vaccine trials successful.(TroVax)(Brief Article)
July 19, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based Oxford Biomedica Plc has completed successful phase I/II trials of TroVax, a gene-based therapeutic vaccine designed to stimulate the immune system to recognise and destroy cancer...

GlaxoSmithKline and Roche scientists form Swiss drug company.(Addex Pharmaceuticals formed)(Brief Article)
July 19, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A number of scientists from UK-based GlaxoSmithKline Plc and Roche Holding AG of Switzerland are breaking away from their parent companies to form a separate company. The new Swiss...

AstraZeneca's Zomig Nasal Spray approved in the EU.(Brief Article)
July 19, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Anglo-Swedish drug group AstraZeneca Plc has won European approval for its Zomig Nasal Spray product. Zomig was first approved in Sweden, where it has been available since February....

Schering AG acquires MAP Medical Technologies.(Brief Article)
July 19, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Schering AG has acquired MAP Medical Technologies Oy, a Finnish radiopharmaceutical company. MAP Medical Technologies, in association with the Karolinska...

Pfizer builds new pharmaceutical development facility in the UK.(Brief Article)
July 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Pfizer Ltd, a UK subsidiary of the global pharmaceutical company Pfizer Inc, is building a new pharmaceutical development facility in Sandwich, Kent. The Sandwich complex serves as...

Avanir files for marketing approval in Sweden. (Avanir Pharmaceuticals' cold sore treatment docosanol 10% cream).(Brief Article)
July 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD US-based Avanir Pharmaceuticals has filed for approval for its docosanol 10% cream, a cold sore treatment, in Europe through a submission to the Swedish Medical Products Agency. ...

Germany's Merck acquires French vitamins, minerals and food supplements firm. (Laboratoires Richelet).(Brief Article)
July 18, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Merck KGaA has acquired Laboratoires Richelet, a privately owned French company which specialises in vitamins, minerals and food supplements. ...

AstraZeneca's new drug shown to lower cholesterol.(Crestor)(Brief Article)
July 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Anglo-Swedish drug group AstraZeneca Plc has revealed data indicating that its experimental drug Crestor is better at cutting cholesterol than the top-selling medicine, Pfizer Inc's...

Belgium's IBA wins proton therapy order in South Korea.(Ion Beam Applications SA)(Brief Article)
July 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Ion Beam Applications SA (IBA), a Belgian particle accelerator maker, has received a contract from the South Korean National Cancer Centre for a proton therapy system. The contract...

deCODE maps asthma gene.(Brief Article)
July 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Scientists at Iceland's deCODE genetics have reportedly mapped the first gene ever shown to have genome-wide significant linkage to asthma. In addition deCODE scientists have located...

MelTec GmbH uses EUR2.3m grant to set up research network.(for biotechnology)(Brief Article)
July 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German biotechnology company MelTec GmbH has been awarded a research grant, worth about EUR2.3m, by the German Federal Ministry for Education, Science, Research and Technology. The...

Boehringer receives US and European marketing approval for Viramune.(Boehringer Ingelheim GmbH)
July 17, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical group Boehringer Ingelheim GmbH has received US and European approval for its antiretroviral drug Viramune (nevirapine). In the US, Viramune has been granted...

DePuy International to sell Osteotech's Grafton DBM in three European markets. (Demineralized Bone Matrix grafts).(Brief Article)
July 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based DePuy International Ltd has entered into marketing services and logistics support agreements with OST Developpement SA, a French subsidiary of Osteotech Inc. The agreements...

GPC Biotech receives milestone payments from Boehringer.(Brief Article)
July 16, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Drug discovery and development company GPC Biotech AG has received milestone payments from pharmaceutical group Boehringer Ingelheim GmbH. The two German companies are partners in a...

ReGen announces successful trial of Alzheimer's disease treatment.(Brief Article)
July 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based ReGen Therapeutics Plc has revealed positive results from its 30-week trial of Colostrinin in the treatment of Alzheimer's disease. According to ReGen, results from the final...

British Biotech prepares to launch new antibiotic trials.(Brief Article)
July 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Research group British Biotech is set to begin phase one trials in October of an antibiotic designed to treat community-acquired pneumonia in hospitals. If successful, the treatment...

AstraZeneca's lung cancer drug Iressa approved in Japan.(Brief Article)
July 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Anglo-Swedish drug group AstraZeneca Plc has said that its Iressa medication has been approved in Japan for treating inoperable or recurring non-small cell lung cancer. The approval...

Scottish scientists hope to develop "memory pills".(Brief Article)
July 15, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Academics at Edinburgh University are hoping to find brain cell substances that go towards forming memories. They then plan to collaborate with other scientists and drug companies to...

Germany's UMS acquires lithotripsy unit in the US.(United Medical Systems International AG to acquire the lithotripsy business unit Alliance Imaging Inc)
July 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UMS United Medical Systems International AG of Germany has agreed to acquire the lithotripsy business unit of US-based Alliance Imaging Inc. The business to be acquired is focussed...

UK Government admits inaccuracies in vaccine assurances.(Brief Article)
July 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD The UK Government has admitted that assurances given over the use of animal products in vaccines were inaccurate. The Department of Health statement relates to claims by ministers...

Roche moves closer to sale of vitamins and fine chemicals business.(Brief Article)
July 12, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Swiss pharmaceutical group Roche has revealed that several potential bidders have started due diligence procedures on its Vitamins and Fine Chemicals Division. Franz Humer, chairman...

Cryo-Cell Europe acquires MainGen GmbH.(Brief Article)
July 11, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Cryo-Cell Europe, N.V., based in the Netherlands, has completed its acquisition of MainGen GmbH from Asta Medica AG, a subsidiary of Degussa AG. MainGen is a licensed GMP clean room...

SkyePharma and GeneMedix to develop extended release hepatitis C drug.(Brief Article)
July 11, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD SkyePharma Plc and GeneMedix Plc have signed an agreement to develop an extended release formulation of a treatment for hepatitis C. SkyePharma will use its DepoFoam injectable drug...

European launch of Schering's Zevalin drug delayed.(Brief Article)
July 11, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Schering AG has announced that the European launch of its cancer treatment Zevalin will be delayed by about a year because of manufacturing problems. The...

Schering acquires European distribution rights for Testogel hormone therapy.(Schering AG)(Brief Article)
July 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Schering AG has signed a distribution agreement with Besins International of France. Under the terms of the agreement Schering will sell and distribute...

UCB launches clinical trials of anti-asthma compound.(UCB S. A.)(Brief Article)
July 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Belgian-based global pharmaceutical company UCB SA has initiated clinical trials with its ucb 35440 compound. The compound is a result of a drug discovery programme based on UCB's...

Rentschler expands biotechnology division.(Dr. Rentschler GmbH and Co.)(Brief Article)
July 10, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD German pharmaceutical company Dr. Rentschler GmbH & Co has expanded its biotechnology division with a EUR20m investment. The investment has reportedly tripled the capacity of the...

Finland's Orion Yhtyma forms wholesale and distribution unit.(Brief Article)
July 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Finnish pharmaceutical company Orion Yhtyma Oyj has created a new wholesale and distribution unit. The move follows the company's acquisition of majority stake in Sweden's Kronans...

Italy's Zambon to invest EUR300m in Spanish R&D centre. (Zambon Group, research and development).(Brief Article)
July 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Italian pharmaceutical company Zambon Group plans to invest EUR300m by 2004 in a research and development (R&D) centre in northeastern Spain. The centre, located in Santa Perpetua de...

Roche-MorphoSys antibody research programme reaches new milestone. (Roche Holding AG).(Brief Article)
July 9, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A Swiss-German joint venture has reportedly made significant progress in efforts to develop drugs that could treat Alzheimer's disease. Switzerland's Roche Holding AG and MorphoSys...

Alliance Unichem raises EUR530m in refinancing deals.(Brief Article)(Statistical Data Included)
July 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD European healthcare and pharmaceutical products distributor Alliance Unichem Plc has raised a total of approximately EUR530m through two financing initiatives. The deals are part of...

Serono SA bids to acquire Genset SA.(Brief Article)(Statistical Data Included)
July 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Swiss biotechnology company Serono SA plans to take over France's Genset SA. The two companies had been discussing the possibility of forming a technology cooperation when the talks...

L'Oreal and Nestle join forces in cosmetic nutritional supplements venture.(Brief Article)
July 8, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A new joint venture based in France aims to develop the global market for cosmetic nutritional supplements. The new company, called Laboratoires INNEOV, is being established by...

Britannia wins EU regulatory approval for Parkinson's disease treatment.(Britannia Pharmaceuticals Ltd.'s APO-go Pen)(Brief Article)(Product Announcement)
July 5, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based Britannia Pharmaceuticals Ltd has received European Union approval for its APO-go Pen apomorphine Parkinson's disease therapy under the Mutual Recognition scheme. The APO-go...

International Brachytherapy s.a. signs distribution deal in Asia.(Daiichi Radioisotope Laboratories Ltd.)(Brief Article)
July 5, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Belgian company International Brachytherapy s.a. has signed a contract for the distribution of its brachytherapy implants in four Asian countries. Under a distribution agreement...

Novuspharma finds potential for BBR 2778 in chronic model of multiple sclerosis.(cancer treatment)(Brief Article)
July 4, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Novuspharma SpA, an Italian biotechnology company focused on cancer, has revealed positive results from a pre-clinical study with BBR 2778. BBR 2778 is Novuspharma's novel...

Roche and Stressgen Biotechnologies form development and marketing alliance.(Roche Holding Ltd.)(StressGen Biotechnologies Corp.)(Brief Article)
July 4, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Swiss healthcare group Roche has formed a global development and marketing collaboration with Canada's Stressgen Biotechnologies Corp. Under the partnership the two companies will...

Arrow Therapeutics signs anti-fungal development deal with Japanese firm.(Toyama Chemical Company Ltd.)(Brief Article)
July 4, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based drug research company Arrow Therapeutics has entered a joint development contract with Japan's Toyama Chemical Co. The two companies intend to develop anti-fungal agents for...

Danish inventors granted patent for PNA antisense chemistry.(Brief Article)
July 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A group of inventors originally working at the University of Copenhagen, Denmark have been granted a US patent which covers the basic composition of matter for the antisense chemistry...

Lundbeck's Cipralex more effective than Cipramil, study shows.(Brief Article)
July 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Danish pharmaceuticals company H. Lundbeck A/S has presented clinical results showing that its new antidepressant drug Cipralex is more effective than its older treatment Cipramil. ...

Smith & Nephew expects to report strong first half of 2002.(Brief Article)
July 3, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK-based medical devices group Smith & Nephew has said that it is continuing to achieve strong growth in its business throughout the world. Sales during the first half of 2002 are...

Roche wins European approval for new hepatitis C drug. (Pegasys).(Brief Article)
July 2, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD European health authorities have approved Pegasys, a new hepatitis C treatment from Swiss healthcare group Roche. The European Medicines Evaluation Agency (EMEA) approved the drug as...

Antisoma trials show DMXAA well tolerated. (cancer treatment).(Brief Article)
July 2, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Antisoma Plc, a UK biopharmaceutical company developing new cancer treatments, has announced positive results from recent Phase I trials. Two trials of Antisoma's vascular targeting...

US advisory panel supports AstraZeneca application to make Prilosec available OTC. (heartburn treatment, over-the-counter drug).(Brief Article)
July 2, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A US federal advisory panel has recommended that the US Food and Drug Administration (FDA) allow over-the-counter (OTC) sales of Prilosec, a prescription heartburn drug made by...

Boots to sell Pheromone's PSC Fertility Monitor in the UK.
July 1, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Canadian companies Tri-Vision International Ltd and Pheromone Sciences Corp have signed a distribution deal for Pheromone's PSC Fertility Monitor in the UK. Under the preliminary...

Protherics files cancer vaccine patents in UK.
July 1, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD UK biotechnology company Protherics Plc has filed patents with the UK Patent Office for a series of immunogens used in a vaccine designed to help prevent the spread of cancer...

Alizyme given go-ahead for Phase IIb clinical trial of obesity treatment.(Brief Article)
July 1, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD Alizyme Plc, a biopharmaceutical company based in the UK, has received regulatory permission to undertake a Phase IIb clinical trial to evaluate ATL-962 for the treatment of obesity. ...

Trial shows positive results for AstraZeneca breast cancer drug.
July 1, 2002... M2 EUROPHARMA-(C)1999-2002 M2 COMMUNICATIONS LTD A major international trial of breast cancer drugs has shown that a drug from Anglo-Swedish group AstraZeneca Plc is more effective than tamoxifen. Anastrozole - produced by...